Randomised, double-blinded, placebo-controlled, clinical trial of ozone therapy as treatment of sudden sensorineural hearing loss

Ragab, Ahmed; Shreef, E; Behiry, Essam; Zalat, S; Noaman, Mostafa M.

doi:10.1017/s0022215108003770

Cited by 12 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At variance with our results, Ragab et al ( 2009 ), after performing a trial in 45 patients with sudden sensorineural hearing loss, by using a reduced volume (100 ml) of major AHT obtained 77% recovery against 40% in placebo control, infused with distilled water!!! The discrepancy may be due to the fact that in these Egyptians patients the hearing loss was acute but nonetheless we critized their imprecise ozonetherapeutic methodology (Bocci et al, 2009e ) and therefore further clinical studies are necessary.…”

Section: The Problems Of Tinnitus and Sudden Hearing Loss (Shl) Is Ocontrasting

confidence: 77%

The Clinical Application of Ozonetherapy

Bocci

2010

Ozone

View full text Add to dashboard Cite

The reader may be eager to examine in which diseases ozonetherapy can be proficiently used and she/he will be amazed by the versatility of this complementary approach (Table 9 1). The fact that the medical applications are numerous exposes the ozonetherapist to medical derision because superficial observers or sarcastic sceptics consider ozonetherapy as the modern panacea. This seems so because ozone, like oxygen, is a molecule able to act simultaneously on several blood components with different functions but, as we shall discuss, ozonetherapy is not a panacea. The ozone messengers ROS and LOPs can act either locally or systemically in practically all cells of an organism. In contrast to the dogma that “ozone is always toxic”, three decades of clinical experience , although mostly acquired in private clinics in millions of patients, have shown that ozone can act as a disinfectant, an oxygen donor, an immunomodulator, a paradoxical inducer of antioxidant enzymes, a metabolic enhancer, an inducer of endothelial nitric oxide synthase and possibly an activator of stem cells with consequent neovascularization and tissue reconstruction .

show abstract

Section: The Problems Of Tinnitus and Sudden Hearing Loss (Shl) Is Ocontrasting

confidence: 77%

The Clinical Application of Ozonetherapy

Bocci

2010

Ozone

View full text Add to dashboard Cite

show abstract

“…Some studies have indicated that SSHL develops when the inner ear does not receive a sufficient oxygen supply [18]. Consequently, hyperbaric oxygen treatment has been used as an alternative option for the treatment of SSHL [19,20]. At Kyoto University Hospital, hyperbaric oxygen therapy has been used as a secondary treatment of choice for glucocorticoid-resistant SSHL [14].…”

Section: Discussionmentioning

confidence: 99%

Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid-resistant sudden sensorineural hearing loss: a prospective clinical trial

Nakagawa

Sakamoto

Hiraumi

et al. 2010

BMC Med

View full text Add to dashboard Cite

BackgroundSudden sensorineural hearing loss (SSHL) is a common condition in which patients lose the hearing in one ear within 3 days. Systemic glucocorticoid treatments have been used as standard therapy for SSHL; however, about 20% of patients do not respond. We tested the safety and efficacy of topical insulin-like growth factor 1 (IGF1) application using gelatin hydrogels as a treatment for SSHL.MethodsPatients with SSHL that showed no recovery to systemic glucocorticoid administration were recruited. We applied gelatin hydrogels, impregnated with recombinant human IGF1, into the middle ear. The primary outcome measure was the proportion of patients showing hearing improvement 12 weeks after the test treatment. The secondary outcome measures were the proportion of patients showing improvement at 24 weeks and the incidence of adverse events. The null hypothesis was that 33% of patients would show hearing improvement, as was reported for a historical control after hyperbaric oxygen therapy.ResultsIn total, 25 patients received the test treatment at a median of 23 days (range 15-32) after the onset of SSHL, between 2007 and 2009. At 12 weeks after the test treatment, 48% (95% CI 28% to 69%; P = 0.086) of patients showed hearing improvement, and the proportion increased to 56% (95% CI 35% to 76%; P = 0.015) at 24 weeks. No serious adverse events were observed.ConclusionsTopical IGF1 application using gelatin hydrogels is well tolerated and may be efficacious for hearing recovery in patients with SSHL that is resistant to systemic glucocorticoids.

show abstract

“…In a study by Ragab et al 26 comprising 45 patients with ISSNHL at Menoufiya University Hospital (Egypt) between 2004 and 2006, the study group (30 patients) was administered ozone therapy through the autohemotherapy method, while the placebo group (15 patients) received sterile distilled water infusions. Both of the patient populations/groups received 10 session treatments twice a week.…”

Section: Discussionmentioning

confidence: 99%

“…In addition to these features, ozone therapy increases antioxidant efficiency and becomes effective for the treatment of ISSNHL by impacting cellular stress. 26 …”

Section: Discussionmentioning

confidence: 99%